Mohammad Hussaini
Overview
Explore the profile of Mohammad Hussaini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gravenmier C, Shah B, Hussaini M, Zhang L
Leuk Lymphoma
. 2024 Jan;
65(5):674-678.
PMID: 38240035
No abstract available.
2.
Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, et al.
Blood Adv
. 2024 Jan;
8(5):1075-1083.
PMID: 38170740
Acute myeloid leukemia (AML) is a heterogeneous malignancy with outcomes largely predicted by genetic abnormalities. Mutations of NPM1 are common in AML, occurring in ∼30% of cases, and generally considered...
3.
Ryder C, Saeed H, Hussaini M
Case Rep Hematol
. 2023 Nov;
2023:8833273.
PMID: 38028985
While the Epstein-Barr virus (EBV) is known to drive lymphomagenesis, it may rarely contribute to transformation of indolent lymphoma as well. Some EBV-related lymphomas represent a diagnostic challenge with important...
4.
Small C, Mukerjee S, Jangam D, Gollapudi S, Singh K, Jaye D, et al.
Int J Lab Hematol
. 2023 Jun;
45(5):726-734.
PMID: 37282364
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic disease derived from plasmacytoid dendritic lineage cells. The disease typically shows skin as well as frequent bone marrow and...
5.
Song J, Moscinski L, Yang E, Shao H, Hussaini M, Zhang H
In Vivo
. 2023 Apr;
37(3):985-993.
PMID: 37103105
Background/aim: Mutations in the ASXL transcriptional regulator 1 (ASXL1) and splicing factor 3b subunit 1(SF3B1) genes are commonly observed in myeloid neoplasms and are independent predicative factors for overall survival...
6.
Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, et al.
Hum Pathol
. 2023 Mar;
136:1-15.
PMID: 36958463
JAK2 rearrangement (JAK2-R) in acute lymphoblastic leukemia (ALL) is rare and often categorized as B-ALL with BCR::ABL1-like features based on the World Health Organization classification. We report 10 patients with...
7.
Dharmasivam M, Kaya B, Wijesinghe T, Azad M, Gonzalvez M, Hussaini M, et al.
J Med Chem
. 2023 Jan;
66(2):1426-1453.
PMID: 36649565
A novel, potent, and selective antitumor agent, namely ()-3-phenyl-1-(2-pyridinyl)-2-propen-1-one 4,4-dimethyl-3-thiosemicarbazone (PPP44mT), and its analogues were synthesized and characterized and displayed strikingly distinctive properties. This activity was mediated by the inclusion...
8.
Shah N, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper T, et al.
Leuk Lymphoma
. 2022 Oct;
64(1):230-233.
PMID: 36301721
No abstract available.
9.
Hennawi M, Pakasticali N, Tashkandi H, Hussaini M
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232559
Mixed-phenotype leukemia (MPAL) is a type of acute leukemia in which the blast population shows mixed features of myeloid, T-lymphoid, and/or B-lymphoid differentiation. MPALs are rare and carry a poor...
10.
Ohgami R, Aung P, Gru A, Hussaini M, Singh K, Querfeld C, et al.
Arch Pathol Lab Med
. 2022 Sep;
147(7):837-846.
PMID: 36170615
Context.—: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcome. BPDCN diagnostically overlaps with entities such as acute myeloid leukemia, histiocytic/dendritic cell neoplasms, and natural...